Amgen and AstraZeneca Lung Cancer Combo Shows Improved Survival in Late-Stage Trial

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LON:AZN) disclosed on Tuesday that their jointly developed drug regimen demonstrated enhanced survival outcomes for individuals suffering from extensive-stage small-cell lung cancer, according to results from a late-stage clinical trial.

The study assessed Amgen's Imdelltra combined with AstraZeneca's Imfinzi as a maintenance therapy, compared against Imfinzi monotherapy. Participants enrolled had not progressed after receiving standard first-line treatment.

The dual-drug approach showed gains across several endpoints, such as overall survival, progression-free survival, and objective response rate. The firms noted that no fresh safety issues arose during the investigation.

Imdelltra earned accelerated approval from the U.S. Food and Drug Administration in 2024 for extensive-stage small-cell lung cancer, and subsequently received traditional approval in 2025. The therapy brought in $513 million in revenue for Amgen during the past year. Oncology products account for roughly 23% of Amgen's overall sales.

Imdelltra is one of Amgen's bispecific antibody assets, a class that links tumor cells to immune cells, prompting the immune system to eliminate malignant cells.

This report was produced with AI assistance and underwent editorial review. For additional details, please refer to our Terms & Conditions.